Cellectar Q3 Loss Widens to $8.0M; Going Concern Reaffirmed With Runway to Q2 2027
CLRB sits 15% above its 52-week low of $1.11.
Summary
Cellectar's Q3 net loss widened to $8.0 million and nine-month cash burn reached $20.3 million, leaving about $21 million of liquidity that funds operations only into Q2 2027 absent new financing. The going-concern warning stands, with $105 million of milestone warrants at $2.65 as the main funding lever.
Key Events · Earnings and Guidance · CLRB
-
Q3 Loss Widens on Trial Ramp
Net loss was $7.97 million for the three months ended September 30, 2026, versus $4.44 million a year earlier; nine-month loss reached $20.56 million versus $16.50 million.
-
Cash Burn and Runway
Cash used in operations was $20.27 million for the nine months, and cash stood at $24.58 million at September 30, 2026. Management cites roughly $21 million of available liquidity, enough only into Q2 2027 without new capital.
-
Going Concern Doubt Reaffirmed
The filing states the uncertainties raise substantial doubt about the company's ability to continue as a going concern, with alternatives including a sale, wind-down, or bankruptcy if financing plans fail.
-
R&D Spending Up 115%
Third-quarter R&D rose to $5.44 million from $2.52 million, driven by Phase 3 WM confirmatory trial startup and the CLR 125 triple-negative breast cancer Phase 1b trial.
Analysis · CLRB · Life Sciences
Cellectar burned $20.3 million of cash in nine months while its net loss widened to $20.6 million from $16.5 million a year earlier, driven by a 115% jump in third-quarter R&D as the Phase 3 Waldenström confirmatory trial and the CLR 125 breast cancer study ramp up. The $24.6 million cash balance looks better than December's $13.2 million only because of the May 2026 financing; management pegs available liquidity at roughly $21 million and says that funds operations only into the second quarter of 2027 without new capital. The filing also reaffirms substantial doubt about going concern and repeats material weaknesses in internal controls. The offset is the $105 million of milestone-based warrants at a $2.65 strike, which only pay out if the Phase 3 first patient enrolls, the FDA accepts the NDA, and the stock trades above $3.45 — well above today's $1.28.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLRB was trading at $1.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1M. The 52-week trading range was $1.11 to $4.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.